Our top pick for
Beginners
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
How to buy Moderna stock | $59.15
Own Moderna stock in just a few minutes.
Moderna, Inc is a biotechnology business based in the US. Moderna shares (MRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Moderna employs 975 staff and has a trailing 12-month revenue of around USD$105.8 million.
How to buy shares in Moderna
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Moderna Find the stock by name or ticker symbol: MRNA. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Moderna reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of USD$59.15, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Moderna, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Moderna. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
How has coronavirus impacted Moderna's share price?
Since the stock market crash in March caused by coronavirus, Moderna's share price has had significant positive movement.
Its last market close was USD$59.15, which is 69.18% up on its pre-crash value of USD$18.23 and 230.26% up on the lowest point reached during the March crash when the shares fell as low as USD$17.91.
If you had bought USD$1,000 worth of Moderna shares at the start of February 2020, those shares would have been worth USD$1,303.79 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,902.49.
Moderna share price
Use our graph to track the performance of MRNA stocks over time.Moderna shares at a glance
Information last updated 2020-09-13.
| Latest market close | USD$59.15 |
|---|---|
| 52-week range | USD$13.53 - USD$95.21 |
| 50-day moving average | USD$69.0897 |
| 200-day moving average | USD$55.1863 |
| Wall St. target price | USD$92.31 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-2.348 |
Compare trading platforms
Compare special offers, low fees and a wide range of types of investments among top trading platforms.The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Moderna stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Moderna price performance over time
Historical closes compared with the last close of $59.15
| 1 week (2020-09-11) | -0.32% |
|---|---|
| 1 month (2020-08-18) | -11.76% |
| 3 months (2020-06-18) | -8.93% |
| 6 months (2020-03-18) | 87.30% |
| 1 year (2019-09-18) | 232.68% |
|---|---|
| 2 years (2018-09-14) | N/A |
| 3 years (2017-09-14) | N/A |
| 5 years (2015-09-14) | N/A |
Moderna financials
| Revenue TTM | USD$105.8 million |
|---|---|
| Gross profit TTM | USD$-436,100,000 |
| Return on assets TTM | -12.41% |
| Return on equity TTM | -22.75% |
| Profit margin | 0% |
| Book value | $7.493 |
| Market capitalisation | USD$23.4 billion |
TTM: trailing 12 months
Shorting Moderna shares
There are currently 22.9 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 14.4% up from 20.0 million last month.
There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.
Moderna's "short interest ratio" (SIR)
Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 11.3 million). Moderna's SIR currently stands at 2.02. In other words for every 100,000 Moderna shares traded daily on the market, roughly 2020 shares are currently held short.
However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 70 shares are currently held short) or 0.0925% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 93 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.
Find out more about how you can short Moderna stock.
Moderna share dividends
We're not expecting Moderna to pay a dividend over the next 12 months.
Moderna overview
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Frequently asked questions
Ask an Expert